CorMedix (CRMD) Stock Price, News & Analysis

Company Overview

CorMedix Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures. The company is engaged in clinical and regulatory activities designed to support product labeling updates and broader patient access. Collaborative partnerships with dialysis providers and distributors help position CorMedix to deliver its therapies into established treatment settings.

Founded in the mid-2000s and headquartered in Piscataway, New Jersey, CorMedix operates with a lean corporate structure that leverages external manufacturing and distribution networks. The company’s senior management team is led by President and Chief Executive Officer Craig Fraser, who brings more than 30 years of experience in the biopharmaceutical industry. CorMedix continues to pursue regulatory milestones and commercial arrangements that aim to expand its reach across North America, Europe and select emerging markets.

Key Stats

• Today's Range: $7.85 to $8.13
• 50-Day Range: $6.25 to $8.05
• 52-Week Range: $6.13 to $17.43
• Volume: 892,425 shs
• Average Volume: 959,162 shs
• Market Capitalization: $621.24 million
• P/E Ratio: 3.96
• Dividend Yield: N/A
• Price Target: $15.00
• Consensus Rating: Moderate Buy

CorMedix Stock Analysis - MarketRank™

CorMedix scored higher than 72% of companies evaluated by MarketBeat, and ranked 193rd out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

CorMedix has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

CorMedix has a consensus price target of $15.00, representing about 89.4% upside from its current price of $7.92.

Amount of Analyst Coverage

CorMedix has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: -68.18%

Earnings Growth

Earnings for CorMedix are expected to decrease by -68.18% in the coming year, from $0.44 to $0.14 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CorMedix is 3.96, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.16.

Price to Earnings Ratio vs. Sector

The P/E ratio of CorMedix is 3.96, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.68.

Price to Book Value per Share Ratio

CorMedix has a P/B Ratio of 1.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CRMD.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CorMedix does not currently pay a dividend.

Dividend Growth

CorMedix does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.70

News Sentiment

CorMedix has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for CorMedix this week, compared to 5 articles on an average week.

Search Interest

34 people have searched for CRMD on MarketBeat in the last 30 days. This is an increase of 467% compared to the previous 30 days.

MarketBeat Follows

7 people have added CorMedix to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CorMedix insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.10% of the stock of CorMedix is held by insiders.

Percentage Held by Institutions

34.18% of the stock of CorMedix is held by institutions.

CRMD Stock Analysis - Frequently Asked Questions

How have CRMD shares performed this year?

CorMedix's stock was trading at $11.63 at the beginning of 2026. Since then, CRMD shares have decreased by 31.9% and is now trading at $7.92.

How were CorMedix's earnings last quarter?

CorMedix Inc (NASDAQ:CRMD) issued its quarterly earnings data on Thursday, March, 5th. The company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.86 by $0.70. The business's quarterly revenue was up 312.1% compared to the same quarter last year.
Read the conference call transcript.

When did CorMedix's stock split?

CorMedix shares reverse split on the morning of Tuesday, March 26th 2019.The 1-5 reverse split was announced on Thursday, March 21st 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 25th 2019. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

Is CorMedix doing a stock buyback?

CorMedix's Board of Directors initiated a stock buyback program on Monday, February 2nd 2026, which authorizes the company to repurchase $75,000,000 in outstanding shares, according to EventVestor. This means that the company could repurchase up to 12.3% of its stock through open market purchases. Stock buyback programs are typically a sign that the company's management believes its shares are undervalued.

Who are CorMedix's major shareholders?

Top institutional investors of CorMedix include Private Advisor Group LLC (0.64%), Bank of New York Mellon Corp (0.47%), Principal Financial Group Inc. (0.23%) and Sigma Planning Corp (0.04%). Insiders that own company stock include Joseph Todisco, Myron Kaplan, Kaufman Beth Zelnick, Elizabeth Hurlburt, Steven W Lefkowitz, Erin Mistry and Alan W Dunton.
View institutional ownership trends.

How do I buy shares of CorMedix?

Shares of CRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of CorMedix own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CorMedix investors own include Voyager Therapeutics (VYGR), Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), AUO (AUOTY), The RMR Group (RMR).

Company Calendar

• Last Earnings: 3/05/2026
• Today: 5/07/2026
• Next Earnings (Estimated): 5/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CRMD
• CIK: 1410098
• Web: www.cormedix.com
• Phone: (908) 517-9500
• Fax: 908-429-4307
• Employees: 30
• Year Founded: 2006

Price Target and Rating

• Average Price Target for CorMedix: $15.00
• High Price Target: $19.00
• Low Price Target: $13.00
• Potential Upside/Downside: +89.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.63
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.00
• Trailing P/E Ratio: 3.96
• Forward P/E Ratio: 18.00
• P/E Growth: N/A
• Net Income: $163.05 million
• Net Margins: 52.31%
• Pretax Margin: 48.13%
• Return on Equity: 52.30%
• Return on Assets: 29.46%

Debt

• Debt-to-Equity Ratio: 0.36
• Current Ratio: 2.11
• Quick Ratio: 1.94

Sales & Book Value

• Annual Sales: $311.71 million
• Price / Sales: 1.99
• Cash Flow: $2.01 per share
• Price / Cash Flow: 3.94
• Book Value: $5.14 per share
• Price / Book: 1.54

Miscellaneous

• Outstanding Shares: 78,440,000
• Free Float: 76,010,000
• Market Cap: $621.24 million
• Optionable: Optionable
• Beta: 1.46